公开(公告)号：US10669310B2

公开(公告)日：2020-06-02

申请号：US16070896

申请日：2017-01-16

Applicant: TOKUSHIMA UNIVERSITY ,  ONCOTHERAPY SCIENCE, INC.

Inventor： Toyomasa Katagiri ,  Takashi Miyamoto ,  Rie Hayashi

IPC: A61K38/10 ,  C07K7/04 ,  A61K38/00 ,  C07K7/00 ,  A61P35/00 ,  A61K38/03

Abstract: The present invention provides peptides containing a structure in which a portion of the dominant negative peptide of BIG3 which inhibits the interaction between BIG3 and PHB2 is substituted with stapling structure(s). Peptides of the present invention have excellent cell growth inhibitory actions. Furthermore, their cell growth inhibitory actions continue for a longer time than the actions of peptides without stapling structures. Therefore, these peptides have features suitable for clinical applications in cancer therapy.

公开(公告)号：US11091517B2

公开(公告)日：2021-08-17

申请号：US16631141

申请日：2018-07-18

Applicant: TOKUSHIMA UNIVERSITY ,  ONCOTHERAPY SCIENCE, INC.

Inventor： Toyomasa Katagiri ,  Tetsuro Yoshimaru ,  Takashi Miyamoto ,  Yasuhide Okamoto

IPC: C07K7/08 ,  A61K47/65 ,  A61P35/00 ,  A61K38/00

Abstract: The present invention provides peptides having a structure in which portions of a dominant-negative peptide of BIG3 which inhibits the interaction between BIG3 and PHB2 are replaced by at least two stapling structures. The peptides of the present invention have excellent cell growth inhibiting activity. The cell growth inhibiting activity lasts longer, compared to a single-stapled peptide. Therefore, the peptides of the present invention have a feature suitable for clinical applications in cancer therapy.